APELLIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.86 USD | +4.03% |
|
+4.90% | -16.71% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,956 | 4,332 | 4,603 | 5,718 | 7,093 | 6,012 | - | - |
| Enterprise Value (EV) 1 | 1,747 | 3,770 | 4,173 | 5,259 | 6,835 | 5,593 | 5,301 | 5,421 |
| P/E ratio | -6.25 x | -12.5 x | -5.35 x | -8.41 x | -13.5 x | -50.1 x | 41 x | 13.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 17.3 x | 69.2 x | 75.8 x | 17.9 x | 7.58 x | 5.11 x | 3.63 x |
| EV / Revenue | - | 15 x | 62.7 x | 69.7 x | 17.2 x | 7.05 x | 4.51 x | 3.27 x |
| EV / EBITDA | -6.07 x | -17.7 x | -7.8 x | -8.87 x | -13.3 x | -75.4 x | 15.3 x | 6.21 x |
| EV / FCF | -8.21 x | -22.7 x | -7.4 x | -10.2 x | -11.5 x | -196 x | 23.2 x | 9.48 x |
| FCF Yield | -12.2% | -4.4% | -13.5% | -9.8% | -8.71% | -0.51% | 4.3% | 10.5% |
| Price to Book | 57.2 x | 21.3 x | 23.2 x | 33.7 x | 36.5 x | 17.7 x | 9.21 x | 4.42 x |
| Nbr of stocks (in thousands) | 63,888 | 75,737 | 97,358 | 110,576 | 118,500 | 120,582 | - | - |
| Reference price 2 | 30.62 | 57.20 | 47.28 | 51.71 | 59.86 | 49.86 | 49.86 | 49.86 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/21/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 250.6 | 66.56 | 75.42 | 396.6 | 793.3 | 1,176 | 1,657 |
| EBITDA 1 | -287.8 | -213.1 | -534.9 | -593.1 | -515.1 | -74.19 | 346.5 | 873 |
| EBIT 1 | -288 | -213.7 | -536.3 | -594.6 | -517.1 | -106.1 | 203.5 | 658.9 |
| Operating Margin | - | -85.27% | -805.67% | -788.38% | -130.39% | -13.38% | 17.31% | 39.75% |
| Earnings before Tax (EBT) 1 | -304.7 | -343 | -746 | -651.5 | -526.5 | -115.9 | 190.3 | 648.3 |
| Net income 1 | -304.7 | -344.9 | -746.4 | -652.2 | -528.6 | -121 | 159 | 481.5 |
| Net margin | - | -137.59% | -1,121.27% | -864.7% | -133.29% | -15.25% | 13.52% | 29.05% |
| EPS 2 | -4.900 | -4.590 | -8.840 | -6.150 | -4.450 | -0.9956 | 1.216 | 3.657 |
| Free Cash Flow 1 | -212.8 | -165.9 | -564.2 | -515.3 | -595.5 | -28.6 | 228.2 | 571.5 |
| FCF margin | - | -66.19% | -847.66% | -683.18% | -150.16% | -3.61% | 19.41% | 34.48% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 65.86% | 65.47% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 143.54% | 118.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/21/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.65 | 60.29 | 14.38 | 16.32 | 22.06 | 22.66 | 44.85 | 94.97 | 110.4 | 146.4 | 162 | 188.9 | 212.5 | 235.6 | 283.7 |
| EBITDA 1 | -127.7 | -89.02 | -128.6 | -148.2 | -152.5 | -163.7 | -174.7 | -120 | -136.6 | -84.04 | -54.74 | -37.07 | -23.94 | -6.826 | - |
| EBIT 1 | -128 | -89.4 | -129 | -148.6 | -152.9 | -164.1 | -175.1 | -120.4 | -137.1 | -84.52 | -61.34 | -37.29 | -18.18 | 0.8503 | 56.85 |
| Operating Margin | -2,265.4% | -148.28% | -897% | -910.57% | -693.41% | -723.88% | -390.41% | -126.82% | -124.17% | -57.74% | -37.85% | -19.74% | -8.55% | 0.36% | 20.04% |
| Earnings before Tax (EBT) 1 | -195.6 | -147.7 | -137.7 | -155.5 | -190.8 | -167.5 | -177.5 | -121.8 | -140 | -87.15 | -56.55 | -43.09 | -25.11 | -6.455 | 55.38 |
| Net income 1 | -195.6 | -147.9 | -138.9 | -156 | -191.3 | -166 | -177.8 | -122 | -140.2 | -88.58 | -56.51 | -43.1 | -25.23 | -6.71 | 53.81 |
| Net margin | -3,461.43% | -245.37% | -966.1% | -955.62% | -867.2% | -732.43% | -396.42% | -128.5% | -127.03% | -60.51% | -34.87% | -22.82% | -11.87% | -2.85% | 18.97% |
| EPS 2 | -2.280 | -1.610 | -1.420 | -1.460 | -1.750 | -1.500 | -1.560 | -1.020 | -1.170 | -0.7300 | -0.4698 | -0.3542 | -0.2065 | -0.0595 | 0.1876 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/28/22 | 5/4/22 | 8/8/22 | 11/7/22 | 2/21/23 | 5/4/23 | 7/31/23 | 11/1/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 209 | 562 | 430 | 459 | 258 | 420 | 711 | 591 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -213 | -166 | -564 | -515 | -596 | -28.6 | 228 | 572 |
| ROE (net income / shareholders' equity) | -312% | -289% | -370% | -354% | -290% | -42.9% | 28.8% | 164% |
| ROA (Net income/ Total Assets) | -103% | -51.1% | -81% | -79.4% | -68.3% | -31.9% | 2.91% | 257% |
| Assets 1 | 296.4 | 674.9 | 921.2 | 821 | 774.5 | 378.8 | 5,466 | 187.6 |
| Book Value Per Share 2 | 0.5400 | 2.690 | 2.040 | 1.530 | 1.640 | 2.810 | 5.420 | 11.30 |
| Cash Flow per Share 2 | -3.390 | -2.140 | -6.670 | -4.840 | -5.010 | -0.5200 | 1.260 | - |
| Capex 1 | 1.69 | 5.42 | 1.1 | 1.52 | 0.77 | 3.64 | 4.93 | 5.09 |
| Capex / Sales | - | 2.16% | 1.66% | 2.02% | 0.19% | 0.46% | 0.42% | 0.31% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/21/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.86
USD
Average target price
82.01
USD
Spread / Average Target
+64.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.71% | 6.01B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- APLS Stock
- Financials Apellis Pharmaceuticals, Inc.
